{"title":"基于纳米颗粒的心肌梗死后药物输送系统","authors":"Minxuan Liu, Chiara Ramponi, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, W. Xiao","doi":"10.53941/ijddp.v1i1.171","DOIUrl":null,"url":null,"abstract":"Review\nNanoparticle-based Drug Delivery System for Post Myocardial Infarction Management\n\nMinxuan Liu, Chiara Ramponi, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, and Wei Xiao *\n\n\nState Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, 222001, China.\n* Correspondence: xw_kanion@163.com\n \n \nReceived: 15 October 2022\nAccepted: 2 November 2022\nPublished: 21 December 2022\n \n\nAbstract: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the world. Myocardial infraction (MI) as one of the most harmful forms of ischaemic heart disease requires rigorous and tempestive approaches which are not met by current clinical interventions. Nanotechnology has developed promising clinical applications for imaging, diagnostic, gene delivery and tissue engineering, which makes this technology a potential candidate for novel therapeutic delivery approach. This review highlights several recent research reports regarding advances in drug delivery using nanoparticle-based (NP) strategies, as well as future challenges and opportunities.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management\",\"authors\":\"Minxuan Liu, Chiara Ramponi, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, W. Xiao\",\"doi\":\"10.53941/ijddp.v1i1.171\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Review\\nNanoparticle-based Drug Delivery System for Post Myocardial Infarction Management\\n\\nMinxuan Liu, Chiara Ramponi, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, and Wei Xiao *\\n\\n\\nState Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, 222001, China.\\n* Correspondence: xw_kanion@163.com\\n \\n \\nReceived: 15 October 2022\\nAccepted: 2 November 2022\\nPublished: 21 December 2022\\n \\n\\nAbstract: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the world. Myocardial infraction (MI) as one of the most harmful forms of ischaemic heart disease requires rigorous and tempestive approaches which are not met by current clinical interventions. Nanotechnology has developed promising clinical applications for imaging, diagnostic, gene delivery and tissue engineering, which makes this technology a potential candidate for novel therapeutic delivery approach. This review highlights several recent research reports regarding advances in drug delivery using nanoparticle-based (NP) strategies, as well as future challenges and opportunities.\",\"PeriodicalId\":94047,\"journal\":{\"name\":\"International journal of drug discovery and pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of drug discovery and pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53941/ijddp.v1i1.171\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of drug discovery and pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53941/ijddp.v1i1.171","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management
Review
Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management
Minxuan Liu, Chiara Ramponi, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, and Wei Xiao *
State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, 222001, China.
* Correspondence: xw_kanion@163.com
Received: 15 October 2022
Accepted: 2 November 2022
Published: 21 December 2022
Abstract: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the world. Myocardial infraction (MI) as one of the most harmful forms of ischaemic heart disease requires rigorous and tempestive approaches which are not met by current clinical interventions. Nanotechnology has developed promising clinical applications for imaging, diagnostic, gene delivery and tissue engineering, which makes this technology a potential candidate for novel therapeutic delivery approach. This review highlights several recent research reports regarding advances in drug delivery using nanoparticle-based (NP) strategies, as well as future challenges and opportunities.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
